Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Summary

This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic Fibrosis-related pulmonary exacerbations (PEx).

Timeline

Start

2023-02-10

Primary completion

2023-09

Completion

2023-09

Publications

• Hamasaki T, He Y, Wu Q, Howard-Anderson J, Boucher HW, Doernberg SB, Holland TL, Powers JH 3rd, Wang J, Diao G, van Duin D, Fowler VG Jr, Chambers HF, Evans SR. A patient-centric paradigm and tool for clinical research: the DOOR is open. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0147825. doi: 10.1128/aac.01478-25. Epub 2025 Nov 24.

Drugs

Indications